The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Roche
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Bayer; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Ipsen; Merck Serono; MSD; Roche; SERVIER
Research Funding - Beigene (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Philippe Merle
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Merck; Roche
Consulting or Advisory Role - Bayer Schering Pharma
 
Weijia Fang
No Relationships to Disclose
 
Eric Assenat
No Relationships to Disclose
 
Hongming Pan
No Relationships to Disclose
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Eisai; Gilead Sciences; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi
Consulting or Advisory Role - Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Exelixis; Genenta Science; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks
Research Funding - Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; Ipsen
 
Zhiwei Li
No Relationships to Disclose
 
Jean-Frederic Blanc
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; MSD; Roche; SERVIER
Consulting or Advisory Role - Bayer; Eisai; Ipsen; Roche
 
Chia-Jui Yen
No Relationships to Disclose
 
Paul J. Ross
Stock and Other Ownership Interests - Perci Health
Honoraria - AstraZeneca; Eisai; Merck; Pierre Fabre; Roche; SERVIER; Shire; Sirtex Medical
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Roche; SERVIER; Sirtex Medical
Speakers' Bureau - Amgen; Boston Scientific; Merck; Servier
Research Funding - Bayer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Roche
 
Sheng Hu
No Relationships to Disclose
 
Tao Zhang
No Relationships to Disclose
 
Albert Tran
No Relationships to Disclose
 
Guoliang Shao
No Relationships to Disclose
 
Mohamed Bouattour
Honoraria - Bayer Schering Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Roche; Sirtex Medical
Speakers' Bureau - Bayer; Roche; SIRTEX Medical
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Ipsen; Roche
 
Yajin Chen
No Relationships to Disclose
 
John Wu
No Relationships to Disclose
 
Bai Li
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Sandra Chica-Duque
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Other Relationship - Turning Point Therapeutics (I)
 
Zhenggang Ren
No Relationships to Disclose